Review
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Aug 16, 2015; 3(8): 694-704
Published online Aug 16, 2015. doi: 10.12998/wjcc.v3.i8.694
Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to date
Kyle Crassini, Stephen P Mulligan, O Giles Best
Kyle Crassini, Stephen P Mulligan, O Giles Best, Northern Blood Research Centre and CLL Australian Research Consortium, Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney NSW 2065, Australia
Author contributions: Crassini K, Mulligan SP and Best OG gathered references and wrote the paper.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. O Giles Best, BSc (Hons), PhD, Northern Blood Research Centre and CLL Australian Research Consortium, Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards, Sydney NSW 2065, Australia. giles.best@sydney.edu.au
Telephone: +61-2-99264860 Fax: +61-2-99265716
Received: November 28, 2014
Peer-review started: November 29, 2014
First decision: December 12, 2014
Revised: December 23, 2014
Accepted: June 4, 2015
Article in press: June 8, 2015
Published online: August 16, 2015
Processing time: 265 Days and 19.7 Hours
Core Tip

Core tip: The treatment of chronic lymphocytic leukemia (CLL) is in a period of unprecedented revolution. A better understanding of the mechanisms that drive the survival and proliferation of CLL cells has led to the development of novel therapeutic strategies. This review article is a timely summary of the results of many of the recent key clinical and pre-clinical studies of novel therapeutic agents for CLL.